ClinicalTrials.gg
Not yet recruitingNCT06942507BRZ-WMUpdated Apr 30, 2025

Zanubrutinib Combined With BR in the First-line Treatment of Waldenström's Macroglobulinemia

An interventional study of Zanubrutinib and Bendamustine + Rituximab in Waldenström's Macroglobulinemia (WM), sponsored by Peking Union Medical College Hospital. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-30.

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
104
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies testing bendamustine in Waldenstrom Macroglobulinemia — 4 open to participants now, 7 under way, none of them phase 3. bendamustine · Waldenstrom Macroglobulinemia.

Planned enrollment
Largest of 10
104 · median 48
Started
2025
with 1 other
No phase
Only one
of the 10
Registered
9th of 10
by date
Lead sponsor
1 of 10
Peking Union Medical College Hospital

Among the 10 studies testing bendamustine in Waldenstrom Macroglobulinemia, this one has the largest planned enrollment, is one of 2 that started in 2025, is the only one with no phase, and was the 9th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

4 of the 10 studies testing bendamustine in Waldenstrom Macroglobulinemia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

About bendamustine

bendamustine: first FDA approval 2008 (TREANDA). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing bendamustine in Waldenstrom Macroglobulinemia, or all of them as a file.
02

Study summary

Current retrospective studies have demonstrated that achieving deep remission following treatment for Waldenström's macroglobulinemia (WM) correlates with prolonged survival. While the bendamustine-rituximab (BR) regimen or single-agent zanubrutinib are currently recommended as first-line therapies, neither achieves optimal deep remission. Additionally, prolonged zanubrutinib monotherapy may lead to cumulative adverse effects. Therefore, this study aims to evaluate the efficacy and safety of the bendamustine-rituximab-zanubrutinib combination regimen as a first-line treatment option for MYD88-mutated WM patients.

03

Conditions studied

  • Waldenström's Macroglobulinemia (WM)

Keywords

  • Rituximab
  • Zanubrutinib
  • MYD88
  • Waldenström's Macroglobulinemia
  • Bendamustine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  1. Previously untreated symptomatic Waldenström macroglobulinemia (WM) meeting IWWM-7 diagnostic criteria:

    1. Presence of monoclonal IgM-type immunoglobulin in serum
    2. Bone marrow infiltration by plasmacytoid lymphocytes or bone marrow showing small lymphocytes/plasma cells/plasmacytoid lymphocytes (any quantity) in the intertrabecular space
    3. Exclusion of other non-Hodgkin lymphoma subtypes
    4. Typical immunophenotype: CD5-/CD10-/CD19⁺/CD20⁺/CD23-/CD79b⁺ /sIgM⁺/CD138- clonal B-cells. Variant phenotypes may show CD5/CD10/CD23 /CD38 positivity or coexistence of clonal B-cells and plasma cells.
  2. MYD88 L265P mutation is detected in peripheral blood or bone marrow.
  3. Serum monoclonal IgM ≥5 g/L.

Exclusion Criteria:

  1. Co-morbidity of uncontrolled infection or disease
  2. Co-morbidity of other active
  3. Co-morbidity of uncontrolled heart disease
  4. Co-morbidity of severe digestive system disorders precluding oral medication
  5. Seropositive for
  6. virus (HBV)-DNA > 1000 copies/mL
  7. Seropositive for (except in the setting of a sustained virologic response)
  8. Neutrophil \<1×10E9/L, \< 75×10E9/L, (ALT) or aspertate aminotransferase (AST) > 2.5 × (ULN), total > 1.5 × ULN, \< 30 mL/min, or receiving renal replacement therapy.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
104 participants (estimated)

Study arms

  • Experimental
    BRZ

    participants recieve 4 to 6 cycles of the zanubrutinib-rituximab-bendamustine regimen

    Drug: Zanubrutinib · Drug: Bendamustine + Rituximab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Complete Response (CR) at 4 to 6 Months After Treatment Initiation

    Time frame: 4 to 6 months after treatment initiation

Secondary outcomes

  1. Number of Participants Achieving Very Good Partial Response (VGPR) at 4 to 6 Months After Treatment Initiation

    Time frame: 4 to 6 months after treatment initiation

  2. Number of Participants Achieving Overall Response (OR) at 4 to 6 Months After Treatment Initiation

    CR + VGPR + partial response (PR)

    Time frame: 4 to 6 months after treatment initiation

  3. Rate of Progression-Free Survival

    Time frame: 2 years

  4. Time to next treatment

    Time frame: 2 years

  5. Rate of Overall Survival

    Time frame: 2 years

  6. Duration of response

    Time frame: 2 years

Other outcomes

  1. Medical resource utilization

    Time frame: 4 to 6 months after treatment initiation

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2025; primary completion for Apr 2027, 23 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 24, 2025
StartEst.
May 1, 2025
Primary completionEst.
Apr 30, 2027
CompletionEst.
Apr 30, 2029
Last update
Apr 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06942507
Responsible party
Jian Li (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Apr 24, 2025
Start date
May 1, 2025 (estimated)
Primary completion
Apr 30, 2027 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Apr 30, 2025

Study contacts

Jian Li
Contact
lijian@pumch.cn
86+18610852525
Jia Chen
Contact
chenjiapumc@yeah.net
86+18813002022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Zanubrutinib · Bendamustine · Rituximab

Start the discussion